Volatile (inhaled) anesthetic agents have cardioprotective effects, which might improve clinical outcomes in patients undergoing coronary-artery bypass grafting (CABG).
C oronary-artery bypass grafting (CABG) is the most common major surgical procedure performed worldwide. 1, 2 More than 300,000 CABG procedures are performed each year in the United States alone, 3 with the incidence of death at 1 year reported to be 2 to 3%. 4, 5 Anesthesia during CABG is typically induced with intravenous drugs only (total intravenous anesthesia) or with a combination of volatile (inhaled) and intravenous agents. When volatile anesthetics are administered before, during, or after periods of organ ischemia, they exert cell-protective effects through multiple mechanisms. These mechanisms include modulation of G-protein-coupled receptors, intracellular signaling pathways, gene expression, potassium channels, and mitochondrial function. 6 Moreover, volatile anesthetics reduce myocardial infarct size in animal models. 7 Several randomized, controlled trials have shown that volatile anesthetics reduce biomarkers of myocardial injury, 7, 8 even if the anesthetics are administered for only a short duration before ischemia. 9 Meta-analyses have shown a reduction in mortality after CABG with volatile anesthetics, [10] [11] [12] a finding that is consistent with observations from moderate-sized randomized, controlled trials. [13] [14] [15] Two international consensus conferences identified the use of volatile anesthetics as a key nonsurgical intervention to improve survival among patients undergoing major surgery, 16, 17 with potential clinical implications for more than 300 million patients each year. 18 Finally, the guidelines from the American College of Cardiology and American Heart Association and the guidelines from the European Association for Cardiothoracic Surgery have suggested that these findings should be applied to the management of anesthesia in patients undergoing cardiac surgery. 19, 20 However, other randomized, controlled trials and meta-analyses did not confirm a benefit of volatile anesthetics, 8, 21, 22 which suggests that this issue is not definitively resolved.
We designed and conducted a large, multicenter, multinational, randomized, controlled trial to test the hypothesis that the use of volatile anesthetics during CABG would result in a lower number of deaths than total intravenous anesthesia.
Me thods

Trial Design
The Mortality in Cardiac Surgery Randomized Controlled Trial of Volatile Anesthetics (MYRIAD) trial was a pragmatic, randomized, single-blind trial that was conducted at 36 centers in 13 countries. The ethics committee at each participating center approved the trial protocol, which is available with the full text of this article at NEJM.org. Details of the rationale, design, and statistical plan have been published previously. 23 The MYRIAD trial was endorsed by the European Association of Cardiothoracic Anesthesiologists and was funded by the Italian Ministry of Health. The funding body had no role in the design of the trial, the collection and analysis of the data, or the writing of the manuscript or in the decision to submit the manuscript for publication. The authors vouch for the completeness and accuracy of the data and analyses and for the fidelity of the trial to the protocol.
Enrollment Criteria and Randomization
All patients scheduled for cardiac surgery were screened for eligibility. Patients were eligible for enrollment if they were 18 years of age or older and if they were scheduled to undergo elective, isolated CABG. Exclusion criteria were planned concomitant valve surgery or aortic surgery; unstable angina; myocardial infarction in the previous 30 days; current use of a sulfonylurea, allopurinol, or theophylline; participation in other randomized, controlled trials in the previous 30 days; general anesthesia in the previous 30 days; nonelective CABG; previous kidney or liver transplantation; cirrhosis; and a previous adverse response to any of the trial anesthetic agents.
Patients who met the enrollment criteria and who provided written informed consent were randomly assigned, in a 1:1 ratio, to an anesthetic regimen that included a volatile anesthetic (desflurane, isoflurane, or sevoflurane) or to total intravenous anesthesia. A randomization list was created with the use of computer-generated, permuted-block sequences, and randomization was stratified according to center. A Web-based central randomization service was used to ensure concealment of the trial-group assignments at 9 centers. The remaining 27 centers used sealed, opaque, sequentially-numbered envelopes so that randomization could be performed as close as T h e ne w e ngl a nd jou r na l o f m e dicine possible to the time of surgery. Patients, personnel who collected data, and personnel who assessed outcomes were unaware of the trial-group assignments. Attending anesthesiologists were aware of the trial-group assignments owing to the nature of the intervention.
Trial Interventions
Patients in the volatile anesthetics group received an anesthetic regimen that included desflurane, isoflurane, or sevoflurane. Attending anesthesiologists were instructed to administer volatile anesthetics for as long as possible during surgery, but no specific drug-administration protocol was mandated. Several strategies to enhance the cardioprotective effect of volatile anesthetics have been proposed. 8, 23, 24 We recommended but did not require implementation of the following three specific strategies: maintenance of at least 1.0 minimum alveolar concentration of the volatile anesthetic (which represents an anesthetic maintenance dose with documented clinical and preconditioning effects) for at least 30 minutes; discontinuation of the volatile agent at least 15 minutes before cardiopulmonary bypass; and at least three wash-in and wash-out periods, which were defined by administration of at least 0.5 minimum alveolar concentration of the volatile agent for 10 minutes interspersed by a wash-out period of 10 minutes or more.
Patients in the total intravenous anesthesia group were not allowed to receive any volatile agents. Either target-controlled infusions or manually-controlled infusions of intravenous agents were allowed in accordance with local practice.
With the exception of the trial anesthetic regimen, all aspects of perioperative management were left to the discretion of the attending physicians. Postoperative monitoring, including the measurement of biomarkers of myocardial necrosis, was performed in accordance with local routine practice.
Data Collection and Follow-up
We collected data on baseline characteristics and coexisting conditions, intraoperative care, postoperative duration of stay in an intensive care unit and in the hospital, major outcomes, adverse events, and protocol deviations. An investigator who was unaware of the trial-group assignments contacted patients by telephone at 30 days and at 1 year after randomization to ascertain vital status and to inquire about any new hospital admissions. In cases of loss to telephone follow-up, we assessed vital status by contacting the patient's general practitioner, contacting the city register office, and sending a letter to the home address of the patient.
Trial Outcomes
The primary outcome of the MYRIAD trial was death from any cause at 1 year. Prespecified secondary outcomes included death from any cause at 30 days, a composite of nonfatal myocardial infarction at 30 days or death at 30 days, death from cardiac causes at 30 days and at 1 year, hospital readmission during follow-up, and duration of stay in an intensive care unit and in the hospital.
We obtained data on several prespecified adverse events, including the following: adverse cerebral outcome (a composite of stroke, delirium, or postoperative cognitive impairment), acute kidney injury, receipt of renal-replacement therapy, surgical revision for bleeding, receipt of highdose inotropic support, and receipt of mechanical circulatory support. We also obtained data on the following anesthesia-related adverse events: allergic reaction (proven or suspected) to anesthetic agents, the propofol infusion syndrome, and malignant hyperthermia. Definitions of trial outcomes and causes of death classified according to validated criteria 25 are provided in the Supplementary Appendix, available at NEJM.org.
Statistical Analysis
We hypothesized that the 1-year incidence of death from any cause would be 3% in the total intravenous anesthesia group, [26] [27] [28] [29] [30] as compared with 2% in the volatile anesthetics group. 15, 31 We calculated that with a sample of 5300 patients in each group (total of 10,600 patients), the trial would have 90% power to detect such a difference at a two-sided alpha level of 0.05. Interim analyses were planned after enrollment of 25%, 50%, and 75% of the planned number of patients. 23, 32, 33 The planned approach to statistical analysis was published previously. 23 Primary analyses were performed according to the intention-to-treat principle. No imputation for missing data was planned; however, we performed an unplanned post hoc multiple imputation analysis of the Volatile vs. Total Intr avenous Anesthesia for CABG primary outcome (details are provided in the Supplementary Appendix). Per-protocol and astreated analyses were also performed.
Dichotomous data (including the primary outcome) were compared with the use of two-tailed chi-square tests with the Yates correction or with the use of Fisher's exact test when appropriate. Continuous variables were compared with the use of the Mann-Whitney U test. Two-sided significance tests were used throughout. For dichotomous outcomes, relative risks and 95% confidence intervals were calculated by means of the two-by-two table method with the use of lognormal approximation. Absolute risk differences and 95% confidence intervals were calculated for continuous outcomes. Data are presented as medians and interquartile ranges or as means and standard deviations. Prespecified subgroup analyses were performed as reported previously (see the Supplementary Appendix).
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A logistic-regression model with stepwise selection was used to identify predictors of death. Clinical data collected before randomization were entered into the model if they had a univariate P value of less than 0.1. Trial group (volatile anesthetics vs. total intravenous anesthesia) was forced into the multivariate model. Collinearity and overfitting were assessed with the use of a stepwise regression model and a Pearson correlation test. In the multivariate analyses, clinical factors or potential confounding variables were expressed as odds ratios with 95% confidence intervals. A post hoc time-toevent analysis of death from any cause was performed, and the hazard ratio and corresponding 95% confidence interval were calculated.
None of the 95% confidence intervals for secondary or safety outcomes were adjusted for multiplicity; therefore, inferences drawn from these intervals may not be reproducible. Data were stored electronically and were analyzed with the use of Stata software, version 15 (StataCorp).
R esult s
Trial Population and Baseline Characteristics
From April 2014 through September 2017, we screened 13,642 patients for eligibility. A total of 5504 patients provided written informed consent, of whom 5400 were enrolled; 2709 were randomly assigned to the volatile anesthetics group and 2691 to the total intravenous anesthesia group (Fig. 1) .
At the time of the second interim analysis, the data and safety monitoring board advised the management committee to stop the trial because of futility, since there was no possibility of achieving the hypothesized effect (the probability was 0.0% for the 1-percentage-point difference in death from any cause at 30 days and 0.6% for the difference at 1 year). Details are provided in the Supplementary Appendix.
The demographic and clinical characteristics of the two groups were similar at baseline (Table 1). Two patients were lost to follow-up at 30 days; therefore, data from 5398 patients (>99.9%) were included in the analysis of death from any cause at 30 days. A total of 47 patients were lost to follow-up at 1 year; therefore, data from 5353 patients (99.1%) were included in the analysis of death from any cause at 1 year (Fig. 1) .
Anesthetic Agents and Process of Care
A total of 122 patients (2.3%) crossed over from the volatile anesthetics group to the total intravenous anesthesia group or vice versa (Fig. 1) . The reasons for crossover are provided in Table S1 Among patients in the volatile anesthetics group with available data, all three of the recommended strategies to enhance the cardioprotective effect of volatile anesthetics were used in 255 of 2581 patients (9.9%). At least one of the three strategies was used in 2522 of 2589 patients in that group (97.4%); maintenance of at least 1.0 minimum alveolar concentration for at least 30 minutes was implemented in 91.8%, discontinuation of volatile anesthetics at least 15 minutes before cardiopulmonary bypass in 42.3%, and at least three wash-in and wash-out periods in 24.0% (Table S3 in Because patients could have met more than one exclusion criterion, the number of patients listed for the individual criteria sum to more than 5430. CABG denotes coronary-artery bypass grafting.
T h e ne w e ngl a nd jou r na l o f m e dicine P = 0.71) ( Table 3 ). The results of the post hoc analyses in which missing data were imputed were similar (Table S4 in the Supplementary Appendix).
At the time of the 30-day follow-up, 38 of 2709 patients (1.4%) in the volatile anesthetics group and 34 of 2689 patients (1.3%) in the total intravenous anesthesia group had died (relative risk, 1.11; 95% CI, 0.70 to 1.76) ( Table 3) . No significant differences between the two groups in any of the secondary outcomes were observed (Table 3 ). There was no significant difference in mortality over time (hazard ratio for death at 1 year, 1.07; 95% CI, 0.76 to 1.49) (Fig. 2) Other mechanical circulatory support 4 (0.1) 12 3 (0.1) 10 * The denominator used to calculate the percentage of centers was 36. † The specific agents that were used are listed in Table S2 in the Supplementary Appendix. Table S7 . Prespecified subgroup analyses, as well as analyses of subgroups defined according to intraoperative characteristics, showed no treatmentby-subgroup interactions or significant differences between groups with respect to death at 30 days or at 1 year (Figs. S1 through S6 and Tables S8 and S9 in the Supplementary Appendix). Univariate and multivariate analyses of the association of baseline variables and trial intervention with death at 30 days and with death at 1 year did not show a significant effect of trial group for either outcome (Tables S10 through S13 in the Supplementary Appendix, with causes of death shown in Tables S14 and S15).
Adverse Effects
No cases of the propofol infusion syndrome or of malignant hyperthermia were reported. Allergic reactions occurred at induction in 9 patients (0.2%; 4 in the volatile anesthetics group and 5 in the total intravenous anesthesia group) and were attributed to antibiotics, muscle relaxants, or hypnotic drugs. A total of 5 patients (4 in the * Data are presented as relative risks for dichotomous outcomes and as absolute risk differences for continuous outcomes. The 95% confidence intervals presented in this table have not been adjusted for multiplicity; therefore, inferences drawn from these intervals may not be reproducible. † P = 0.71. ‡ Patients with missing data included patients who died, patients for whom no information on readmission was available, and patients for whom no information on vital status was available. § These data are absolute risk differences. T h e ne w e ngl a nd jou r na l o f m e dicine volatile anesthetics group and 1 in the total intravenous anesthesia group) had a severe reaction to protamine. Three patients died during surgery from cardiogenic shock. Additional prespecified adverse events are reported in Table  S16 in the Supplementary Appendix; no significant between-group differences were observed. In particular, we observed no difference in the incidence of myocardial infarction.
Discussion
In this pragmatic, multicenter, randomized, single-blind trial involving patients undergoing elective, isolated CABG, intraoperative anesthesia with a volatile anesthetic did not result in a significantly lower number of deaths at 1 year than total intravenous anesthesia. Moreover, the outcomes of death at 30 days, a composite of perioperative nonfatal myocardial infarction at 30 days or death at 30 days, and other major secondary outcomes did not differ significantly between the two groups. Finally, the incidence of adverse events also did not differ significantly between the groups.
Previous preclinical studies, observational studies, moderate-sized randomized, controlled trials, meta-analyses of randomized, controlled trials, and consensus opinion had all suggested that the use of volatile anesthetics during cardiac surgery, and especially during CABG, would enhance myocardial protection and reduce the risk of perioperative myocardial infarction, myocardial dysfunction, and death. [11] [12] [13] [14] [15] 31 Several patterns of administration of volatile anesthetic agents were investigated in previous studies, ranging from a single 5-minute exposure to volatile anesthetics before myocardial ischemia 9 to total inhalational anesthesia. 15 Among various possible strategies for enhancing the cardioprotective effect of volatile anesthetics, the three strategies suggested in our trial were associated with the most promising findings. Possible explanations for our failure to confirm results from previous studies include the known limited reproducibility of preclinical studies in human trials and the risk of type I error in smaller studies.
In our trial, in contrast to most previous studies, approximately one third of the patients enrolled underwent off-pump CABG. Although inclusion of these patients may have influenced our findings, previous randomized, controlled trials reported a lower postoperative troponin level in patients who underwent off-pump CABG with volatile anesthetics than in those who underwent off-pump CABG with total intravenous anesthesia.
34-37 Accordingly, we included such patients. 23 Moreover, a prespecified subgroup analysis that compared the primary outcome in patients who underwent on-pump CABG with those who underwent off-pump CABG in our trial did not suggest a differential treatment effect.
Another factor that may have influenced the results of our trial is the coadministration of propofol during the induction of anesthesia, which has been shown to attenuate the potential beneficial effect of volatile anesthetics. 15, 38 However, several studies have shown beneficial effects of volatile anesthetics even with coadministration of propofol, 9, 14, 39 with some trials even suggesting that myocardial protection may actually be enhanced by the combination therapy. 8 Opioids could have a preconditioning cardioprotective effect that would potentially mask the effect of volatile agents. However, previous trials that showed a beneficial effect of volatile agents did not restrict or specify an intraoperative opioid regimen, 14, 15 and cardioprotective doses of opioids are much higher than the doses used for anesthesia in clinical practice. The inset shows the same data on an enlarged y axis. Volatile anesthetics
Total intravenous anesthesia
Several limitations regarding our trial intervention should be considered in interpreting our findings. First, we did not use a strict protocol for the administration of volatile anesthetics and the management of concomitant anesthetic drugs. However, our trial was pragmatic and was aimed at replicating a real-life environment. For the same reason, we did not compare total intravenous anesthesia with total inhalational anesthesia because the latter strategy is seldom used in adult surgery, and previous trials also allowed for administration of intravenous anesthetics in the volatile anesthetics group. [13] [14] [15] Second, we allowed clinicians to use any one of three volatile agents; however, previous metaanalyses had suggested that these agents have equivalent protective effects. 12 Third, implementation of all three strategies of volatile anesthetic administration that we recommended to enhance cardioprotection occurred in relatively few patients, although at least one of the recommended strategies was implemented in more than 95% of the patients in the volatile anesthetics group.
Several other trial limitations should also be noted. First, our trial was stopped early, which increased the risk of type 2 error for the secondary outcomes. However, there was no trend toward a beneficial effect of volatile anesthetics for these outcomes, and the survival plots were almost identical. Second, we did not mandate postoperative measurement of troponin. Thus, our diagnosis of postoperative myocardial infarction had limited sensitivity. Third, the number of deaths at 1 year in our trial was consistent with that in recent literature [26] [27] [28] [29] [30] but lower than that in the two largest randomized, controlled trials that favored volatile anesthetics. 14, 15 Therefore, the possibility exists that a beneficial effect could have been observed in a population with higher mortality. Fourth, our trial focused on patients who underwent isolated elective CABG. Thus, we cannot comment on whether volatile anesthetics would have a different effect on patients undergoing complex surgery. However, previous trials and meta-analyses showed no benefit in other types of cardiac surgery or in combined procedures. 12, 40 In conclusion, among patients undergoing elective, isolated CABG, an intraoperative anesthetic regimen that included volatile anesthetics did not result in significantly fewer deaths at 30 days or 1 year than a regimen of total intravenous anesthesia.
